These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 34183144)
21. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy. Blair HA CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489 [TBL] [Abstract][Full Text] [Related]
22. Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. Schorling DC; Pechmann A; Kirschner J J Neuromuscul Dis; 2020; 7(1):1-13. PubMed ID: 31707373 [TBL] [Abstract][Full Text] [Related]
23. Gene therapy for spinal muscular atrophy: the Qatari experience. Ali HG; Ibrahim K; Elsaid MF; Mohamed RB; Abeidah MIA; Al Rawwas AO; Elshafey K; Almulla H; El-Akouri K; Almulla M; Othman A; Musa S; Al-Mesaifri F; Ali R; Shahbeck N; Al-Mureikhi M; Alsulaiman R; Alkaabi S; Ben-Omran T Gene Ther; 2021 Nov; 28(10-11):676-680. PubMed ID: 34276047 [TBL] [Abstract][Full Text] [Related]
24. Curing SMA: Are we there yet? Reilly A; Chehade L; Kothary R Gene Ther; 2023 Feb; 30(1-2):8-17. PubMed ID: 35614235 [TBL] [Abstract][Full Text] [Related]
25. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238 [TBL] [Abstract][Full Text] [Related]
26. Room to improve: The diagnostic journey of Spinal Muscular Atrophy. Carter M; Tobin A; Coy L; McDonald D; Hennessy M; O'Rourke D Eur J Paediatr Neurol; 2023 Jan; 42():42-46. PubMed ID: 36525883 [TBL] [Abstract][Full Text] [Related]
27. Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screening. Deng S; Lee BH; Ciafaloni E J Child Neurol; 2022 Jan; 37(1):43-49. PubMed ID: 34753336 [TBL] [Abstract][Full Text] [Related]
33. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Erdos J; Wild C Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607 [TBL] [Abstract][Full Text] [Related]
34. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026 [TBL] [Abstract][Full Text] [Related]
35. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Vill K; Schwartz O; Blaschek A; Gläser D; Nennstiel U; Wirth B; Burggraf S; Röschinger W; Becker M; Czibere L; Durner J; Eggermann K; Olgemöller B; Harms E; Schara U; Kölbel H; Müller-Felber W Orphanet J Rare Dis; 2021 Mar; 16(1):153. PubMed ID: 33789695 [TBL] [Abstract][Full Text] [Related]
36. Progress in spinal muscular atrophy research. Wurster C; Petri S Curr Opin Neurol; 2022 Oct; 35(5):693-698. PubMed ID: 35942665 [TBL] [Abstract][Full Text] [Related]
37. Onasemnogene Abeparvovec: First Global Approval. Hoy SM Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752 [TBL] [Abstract][Full Text] [Related]
38. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254 [TBL] [Abstract][Full Text] [Related]
39. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249 [TBL] [Abstract][Full Text] [Related]